SecSonar.com

Korro Bio, Inc. (KRRO)

Korro Bio, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Korro Bio, Inc. (KRRO) is a Biotechnology company based in US with a market capitalization of $129.6M. Free cash flow was negative at -$79.1M. This page tracks KRRO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 112 employees · IPO Oct 3, 2019

Valuation

Valuation & price

$10.18 · as of May 17, 2026 · -80.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.52

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$48.60$26.94$5.28Jul 25Dec 25Jul 26Jul 7, 25$12.58Jul 9, 25$14.72Jul 11, 25$12.71Jul 15, 25$12.66Jul 17, 25$13.83Jul 21, 25$13.34Jul 23, 25$16.85Jul 25, 25$16.01Jul 29, 25$15.16Jul 31, 25$14.96Aug 4, 25$15.49Aug 6, 25$15.70Aug 11, 25$15.05Aug 13, 25$18.93Aug 15, 25$20.26Aug 19, 25$19.14Aug 21, 25$20.55Aug 25, 25$20.07Aug 27, 25$21.58Aug 29, 25$23.08Sep 3, 25$26.04Sep 5, 25$33.18Sep 9, 25$36.12Sep 11, 25$34.39Sep 16, 25$31.14Sep 18, 25$33.22Sep 22, 25$34.21Sep 24, 25$38.53Sep 26, 25$40.66Sep 30, 25$47.89Oct 2, 25$45.72Oct 6, 25$43.70Oct 8, 25$45.81Oct 10, 25$42.97Oct 14, 25$45.78Oct 16, 25$48.60Oct 21, 25$41.44Oct 23, 25$37.50Oct 27, 25$39.58Oct 29, 25$38.78Oct 31, 25$40.91Nov 4, 25$33.85Nov 6, 25$32.57Nov 10, 25$32.62Nov 12, 25$31.42Nov 14, 25$6.07Nov 18, 25$6.22Nov 20, 25$5.99Nov 25, 25$5.73Nov 28, 25$5.70Dec 2, 25$5.28Dec 4, 25$6.81Dec 8, 25$7.54Dec 10, 25$7.83Dec 12, 25$8.23Dec 16, 25$8.22Dec 18, 25$7.82Dec 22, 25$8.21Dec 24, 25$8.41Dec 29, 25$8.01Jan 2, 26$8.05Jan 6, 26$8.26Jan 8, 26$9.15Jan 12, 26$8.94Jan 14, 26$9.00Jan 16, 26$8.78Jan 21, 26$9.47Jan 23, 26$10.73Jan 27, 26$10.74Jan 29, 26$13.31Feb 2, 26$13.05Feb 4, 26$12.26Feb 9, 26$12.72Feb 11, 26$12.29Feb 13, 26$11.17Feb 18, 26$11.24Feb 20, 26$11.11Feb 24, 26$11.93Feb 26, 26$12.10Mar 2, 26$11.50Mar 4, 26$11.15Mar 6, 26$11.18Mar 10, 26$11.48Mar 12, 26$11.50Mar 17, 26$12.31Mar 19, 26$11.06Mar 23, 26$11.27Mar 25, 26$10.92Mar 27, 26$10.40Mar 31, 26$11.32Apr 2, 26$14.00Apr 7, 26$13.91Apr 9, 26$13.08Apr 13, 26$13.69Apr 15, 26$13.68Apr 17, 26$14.39Apr 22, 26$13.99Apr 24, 26$12.89Apr 28, 26$12.80Apr 30, 26$13.49May 4, 26$13.03May 6, 26$13.34May 8, 26$12.05May 12, 26$11.22May 14, 26$11.08May 18, 26$9.97May 20, 26$10.01May 22, 26$11.61May 28, 26$13.40Jun 1, 26$12.93Jun 3, 26$11.08Jun 5, 26$10.72Jun 9, 26$10.94Jun 11, 26$10.53Jun 15, 26$11.66Jun 17, 26$11.05Jun 22, 26$13.90Jun 24, 26$13.77Jun 26, 26$12.70Jul 2, 26$14.00
$5.2852-week range$51.36
Loading valuation history…

Fundamentals

Key fundamentals

$129.6M

Market cap

—

Revenue growth (YoY)

33.0%

Gross margin

-$79.1M

Free cash flow (USD)

-$31.7M

Net debt

Net cash position

5.3%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2017 → 2025

FY 2017$0.00FY 2018$0.00FY 2019$28.9MFY 2020$37.0MFY 2021$14.1MFY 2022$0.00FY 2023$0.00FY 2024$2.3MFY 2025$6.4M
$0$6.4M

Free cash flow by year

2017 → 2025

FY 2017$-16.5MFY 2018$-17.5MFY 2019$33.2MFY 2020$-51.9MFY 2021$-36.5MFY 2022$-58.9MFY 2023$-75.1MFY 2024$-78.0MFY 2025$-79.1M
-$16.5M-$79.1M

Gross margin by year

2021 → 2025

FY 202172.7%FY 2024100.0%FY 202533.0%
72.7%33.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

7

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $2.5M · 10b5-1 PlanFORMELA JEAN FRANCOIS · Director · $2.5MJun 24, 2026Filing
  • Insider sellInsider Sell $37KDolan Oliver · Senior Vice President, Finance · $36.6KJun 17, 2026Filing
  • Insider sellInsider Sell $72KCerio Jeffrey · General Counsel · $71.6KJun 17, 2026Filing
  • Insider sellInsider Sell $37KVincent Loic A · Chief Scientific Officer · $37KJun 17, 2026Filing
  • Insider sellInsider Sell $34KChappell Todd · Chief Operating Officer · $34.3KJun 17, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 11, 2026Filing
  • Insider sellInsider Sell $197KAiyar Ram · Director, President and CEO · $196.7KJun 2, 2026Filing
  • Insider sellInsider Sell $40K · 10b5-1 PlanFORMELA JEAN FRANCOIS · Director · $39.9KJun 1, 2026Filing
  • 8-K eventNew Therapeutic Candidate AddedMay 19, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing

Questions

Frequently asked questions

What is Korro Bio, Inc.'s market cap?

Korro Bio, Inc. (KRRO) has a market capitalization of $129.6M.

What is KRRO's P/E ratio?

A meaningful P/E ratio is not available for KRRO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is KRRO's price-to-book (P/B) ratio?

KRRO trades at 2.52 times book value per share.

Are insiders buying KRRO stock?

SEC Form 4 filings show no open-market insider buys at Korro Bio, Inc. in the last 90 days (7 sells).

Same arena

Related companies in Biotechnology

BDTX

Black Diamond Therapeutics, Inc.

$130.1M

IKT

Inhibikase Therapeutics, Inc.

$125.3M

CRDF

Cardiff Oncology, Inc.

$124.8M

MIST

Milestone Pharmaceuticals Inc.

$124.1M

HRTX

Heron Therapeutics, Inc.

$135.1M

ALPS

Alps Group Inc

$121.8M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.